Every few years, a familiar policy reflex returns: ban advertising and hope the problem goes away.The UK has now pushed ahead ...

Health Canada approved last month two  brand names for generic semaglutide products, Plosbrio  and  Poviztra, which contain ...

When endocrinologist Dan Bessesen, MD, looked online and saw how easy it would be for him to purchase a weight loss drug from ...

Over 27 percent of adults worldwide with obesity qualify for GLP-1 weight loss medicines but access remains unequal.

Most U.S. adults have risk factors tied to a little-known condition called CKM syndrome, which connects heart disease, kidney ...

An illness connecting heart disease, kidney problems, diabetes, and obesity is a major high-risk health cycle affecting ...

Ozempic works by mimicking a hormone that reduces appetite and helps control blood sugar; users report the silencing of “food ...

January’s designation as National Dog Walking Month is encouraging local pet owners to leash up and step outside, promoting ...

A new study offers fresh hope for people living with type 2 diabetes and obesity. Researchers report progress toward a pill ...

November Faculty and Staff GrantsBridging the GapNaazneen Barma, Josef Korbel School of Global and Public AffairsFunder: ...

GLP-1 meds are are highly effective at treating diabetes, obesity and other conditions. But when people stop using them, the ...

Discontinuing obesity medicines often means the weight comes back and people lose the cardiovascular and metabolic benefits ...